4-week Serial FIT Analysis in Patients With CRC
Launched by NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST · Jan 24, 2020
Trial Information
Current as of May 22, 2025
Completed
Keywords
ClinConnect Summary
Colorectal cancer (CRC) remains a leading cause of cancer death in the UK and worldwide. Improving outcomes depends in part on achieving earlier diagnosis of the disease.
The Faecal Immunochemical Test (FIT) is replacing the less accurate Faecal Occult Blood Test (FOBT) in the UK and has the potential to help achieve earlier stage diagnosis of CRC. Whilst FIT has been validated as a screening test for the Bowel Cancer Screening Programme (BCSP), its role in diagnosing CRC in symptomatic populations is yet to be defined.
Nottingham is a pioneering centre using FIT to stratify risk and dete...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically confirmed colorectal cancer
- Exclusion Criteria:
- • Less than 18 years old
- • Not attending Nottingham University Hospitals for diagnosis/treatment (attending another trust)
- • No histological diagnosis of colorectal cancer
- • Unable to provide informed consent - for example due to language barriers or lacking capacity to join study
About Nottingham University Hospitals Nhs Trust
Nottingham University Hospitals NHS Trust is a leading healthcare provider in the UK, dedicated to delivering high-quality patient care and advancing medical research. Comprising two major hospitals, Queen's Medical Centre and Nottingham City Hospital, the Trust is at the forefront of clinical innovation and education. With a strong emphasis on translational research, Nottingham University Hospitals NHS Trust actively sponsors clinical trials aimed at improving treatment outcomes and understanding various health conditions. The Trust collaborates with academic institutions, healthcare professionals, and industry partners to foster a robust research environment that enhances clinical practice and contributes to evidence-based medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nottingham, Nottinghamshire, United Kingdom
Patients applied
Trial Officials
David Humes, MBBS
Principal Investigator
Nottingham University Hospitals NHS Trust
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials